title: Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients.
abstract: BACKGROUND
  It is often a clinical dilemma to determine when to collect autologous peripheral blood progenitor cells (PBPCs) in patients who received prior chemotherapy. It is also challenging to predict if the collected cells will be enough for one or two transplants.
  
  
  METHODS
  A total of 103 PBPC donors were followed to evaluate factors that predict poor autologous PBPC collection. The donors were categorized into three groups: plasma cell disorders (PCDs), lymphomas, and normal allogeneic donors.
  
  
  RESULTS
  Our evaluation showed that platelet (PLT) count before growth factor administration significantly correlated with total CD34+ cell yield (Spearman r = 0.38, p < 0.001). Further analysis showed this correlation was only significant in plasma cell disease patients who received prior chemotherapy (Spearman r = 0.5, p = 0.008). Baseline PLT counts did not correlate with PBPC collection yield in untreated PCD, lymphoma, and normal allogeneic donors. In addition, daily PLT count during PBPC harvest correlated with CD34+ cell yield for that day (Spearman r = 0.41, p < 0.001). With a multiple linear regression model (adjusted R(2) = 0.31, AIC = 63.1), it has been determined that the baseline PLT count significantly correlates with total CD34+ cell yield in treated PCD patients.
  
  
  CONCLUSIONS
  Baseline PLT count is a sensitive indicator of autologous PBPC mobilization in PCD patients who received prior chemotherapy. This finding may be considered before growth factor administration to determine the optimal period to mobilize treated PCD patients and to predict if enough cells can be collected for one or two transplants.
authors.affiliation: Transfusion Medicine, Department of Pathology and Division of Hematology/Oncology, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA. zubair.abba@mayo.edu
authors.forename: Abba C
authors.initials: AC
authors.lastname: Zubair
authors.forename: Rhonda
authors.initials: R
authors.lastname: Grant
authors.forename: Wenting
authors.initials: W
authors.lastname: Wu
authors.forename: Han
authors.initials: H
authors.lastname: Tun
authors.forename: Candido
authors.initials: C
authors.lastname: Rivera
authors.forename: Alvaro
authors.initials: A
authors.lastname: Moreno-Aspitia
authors.forename: Michael
authors.initials: M
authors.lastname: Joyce
authors.forename: Vivek
authors.initials: V
authors.lastname: Roy
authors.forename: Gerardo
authors.initials: G
authors.lastname: Colon-Otero
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Solberg
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D002454:Cell Differentiation; D006402:Hematologic Diseases / Q000473:pathology* / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D008875:Middle Aged; D008954:Models, Biological; D010950:Plasma Cells / Q000166:cytology*; D010976:Platelet Count; D012372:ROC Curve; D012680:Sensitivity and Specificity; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34